
Ronald Gust

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2599161/publications.pdf Version: 2024-02-01



RONALD CLIST

#	Article	IF	CITATIONS
1	Investigations of the reactivity, stability and biological activity of halido (NHC)gold(<scp>i</scp>) complexes. Dalton Transactions, 2022, 51, 1395-1406.	1.6	13
2	Validated Capillary Zone Electrophoresis Method for Impurity Profiling and Determination of Nill(3-OMe-Salophene). Separations, 2022, 9, 25.	1.1	5
3	Development of methylated cobalt–alkyne complexes with selective cytotoxicity against COXâ€positive cancer cell lines. Archiv Der Pharmazie, 2022, 355, 2100408.	2.1	6
4	Recent development of gold(<scp>i</scp>) and gold(<scp>iii</scp>) complexes as therapeutic agents for cancer diseases. Chemical Society Reviews, 2022, 51, 5518-5556.	18.7	70
5	Investigating the antibacterial activity of salen/salophene metal complexes: Induction of ferroptosis as part of the mode of action. European Journal of Medicinal Chemistry, 2021, 209, 112907.	2.6	34
6	Zeta potential changing nanoemulsions based on a simple zwitterion. Journal of Colloid and Interface Science, 2021, 585, 126-137.	5.0	33
7	Synthesis, characterization and biological activity of bis[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2 <i>H</i> -imidazol-2-ylidene]gold(<scp>i</scp>) complexes. Dalton Transactions, 2021, 50, 4270-4279.	1.6	7
8	Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy. European Journal of Medicinal Chemistry, 2021, 216, 113285.	2.6	1
9	Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site. Journal of Medicinal Chemistry, 2021, 64, 5766-5786.	2.9	4
10	Internal and External Influences on Stability and Ligand Exchange Reactions in Bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2 <i>H</i> -imidazol-2-ylidene]gold(I) Complexes. Inorganic Chemistry, 2021, 60, 8546-8553.	1.9	5
11	In vitro evaluation of cytotoxic effects of di (2-ethylhexyl) phthalate (DEHP) produced by Bacillus velezensis strain RP137 isolated from Persian Gulf. Toxicology in Vitro, 2021, 73, 105148.	1.1	7
12	Probing the Paradigm of Promiscuity for Nâ€Heterocyclic Carbene Complexes and their Protein Adduct Formation. Angewandte Chemie, 2021, 133, 20081-20085.	1.6	1
13	Probing the Paradigm of Promiscuity for Nâ€Heterocyclic Carbene Complexes and their Protein Adduct Formation. Angewandte Chemie - International Edition, 2021, 60, 19928-19932.	7.2	24
14	Determination of Relative Stabilities of Metalâ€Peptide Bonds in the Gas Phase. Chemistry - A European Journal, 2021, 27, 16401-16406.	1.7	1
15	Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators. European Journal of Medicinal Chemistry, 2020, 185, 111748.	2.6	12
16	A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma. Oncogene, 2020, 39, 1080-1097.	2.6	31
17	<i>N</i> -Heterocyclic Carbene Gold(I) Complexes: Mechanism of the Ligand Scrambling Reaction and Their Oxidation to Gold(III) in Aqueous Solutions. Inorganic Chemistry, 2020, 59, 15312-15323.	1.9	27
18	Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177. Molecules, 2020, 25, 4585.	1.7	10

#	Article	IF	CITATIONS
19	Cell deathâ€inducing properties of selected dendrimers against different breast cancer and leukemia cell lines. Archiv Der Pharmazie, 2020, 353, 2000209.	2.1	4
20	Amide and ester derivatives of chlorido[4-carboxy-1,2-disalicylideneaminobenzene]iron(<scp>iii</scp>) as necroptosis and ferroptosis inducers. Dalton Transactions, 2020, 49, 6842-6853.	1.6	16
21	Phosphorylated PEG-emulsifier: Powerful tool for development of zeta potential changing self-emulsifying drug delivery systems (SEDDS). European Journal of Pharmaceutics and Biopharmaceutics, 2020, 150, 77-86.	2.0	25
22	Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators. European Journal of Medicinal Chemistry, 2020, 192, 112191.	2.6	13
23	Top-down mass spectrometry reveals multiple interactions of an acetylsalicylic acid bearing Zeise's salt derivative with peptides. Journal of Biological Inorganic Chemistry, 2020, 25, 285-293.	1.1	2
24	Synthesis, characterization and biological activity of bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(i) complexes. Dalton Transactions, 2020, 49, 5471-5481.	1.6	13
25	Lipophilic Arginine Esters: The Gateway to Preservatives without Side Effects. Molecular Pharmaceutics, 2020, 17, 3129-3139.	2.3	8
26	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARÎ ³ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells. European Journal of Medicinal Chemistry, 2020, 195, 112258.	2.6	6
27	Synthesis and Characterization of Telmisartanâ€Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia. ChemMedChem, 2020, 15, 1067-1077.	1.6	5
28	Thiolated chitosans: Are Cys-Cys ligands key to the next generation?. Carbohydrate Polymers, 2020, 242, 116395.	5.1	25
29	Novel strategies to eradicate resistant cells in chronic myeloid leukemia. Future Medicinal Chemistry, 2020, 12, 2089-2092.	1.1	0
30	Microindoline 581, an Indole Derivative from Sp. RP581 as A Novel Selective Antineoplastic Agent to Combat Hepatic Cancer Cells: Production, Optimization and Structural Elucidation. Iranian Journal of Pharmaceutical Research, 2020, 19, 290-305.	0.3	0
31	A New Approach in Cancer Treatment: Discovery of Chlorido[<i>N</i> , <i>N</i> ′-disalicylidene-1,2-phenylenediamine]iron(III) Complexes as Ferroptosis Inducers. Journal of Medicinal Chemistry, 2019, 62, 8053-8061.	2.9	48
32	Zeta potential changing self-emulsifying drug delivery systems: A promising strategy to sequentially overcome mucus and epithelial barrier. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 40-49.	2.0	38
33	An Aminoglycoside Antibacterial Substance, S-137-R, Produced by Newly Isolated Bacillus velezensis Strain RP137 from the Persian Gulf. Current Microbiology, 2019, 76, 1028-1037.	1.0	14
34	Covalently binding mucoadhesive polymers: N-hydroxysuccinimide grafted polyacrylates. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 161-167.	2.0	14
35	In vitro evaluation of intravesical mucoadhesive self-emulsifying drug delivery systems. International Journal of Pharmaceutics, 2019, 564, 180-187.	2.6	11
36	Fluorination as tool to improve bioanalytical sensitivity and COX-2-selective antitumor activity of cobalt alkyne complexes. Dalton Transactions, 2019, 48, 15856-15868.	1.6	25

#	Article	IF	CITATIONS
37	Reactive keratin derivatives: A promising strategy for covalent binding to hair. Journal of Colloid and Interface Science, 2019, 534, 533-541.	5.0	20
38	Studies on the stability of the anticancer-active [N,N′-bis(salicylidene)-1,2-phenylenediamine]chloridoiron(III) complex under pharmacological-like conditions. Inorganica Chimica Acta, 2019, 487, 76-80.	1.2	12
39	Chlorinated cobalt alkyne complexes derived from acetylsalicylic acid as new specific antitumor agents. Dalton Transactions, 2018, 47, 4341-4351.	1.6	28
40	Zeise's salt as powerful platinating agent for proteins investigated by top-down-mass spectrometry. Journal of Inorganic Biochemistry, 2018, 189, 53-57.	1.5	2
41	Synthesis and Biological Evaluation of Zeise's Salt Derivatives with Acetylsalicylic Acid Substructure. International Journal of Molecular Sciences, 2018, 19, 1612.	1.8	14
42	Importance of 5/6-aryl substitution on the pharmacological profile of 4ʹ-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1ʹ-biphenyl]-2-carboxylic acid derived PPARγ agonists. European Journal of Medicinal Chemistry, 2017, 126, 590-603.	2.6	8
43	Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs. Coordination Chemistry Reviews, 2016, 329, 191-213.	9.5	292
44	New telmisartan-derived PPARÎ ³ agonists: Impact of the 3D-binding mode on the pharmacological profile. European Journal of Medicinal Chemistry, 2016, 124, 138-152.	2.6	22
45	Untersuchungen zur biologischen Aktivitädes Zeiseâ€Salzes und seiner Derivate. Angewandte Chemie, 2015, 127, 2876-2879.	1.6	3
46	The Biological Activity of Zeise's Salt and its Derivatives. Angewandte Chemie - International Edition, 2015, 54, 2834-2837.	7.2	18
47	Fluorinated Fe(III) Salophene Complexes: Optimization of Tumor Cell Specific Activity and Utilization of Fluorine Labeling for in Vitro Analysis. Journal of Medicinal Chemistry, 2015, 58, 588-597.	2.9	24
48	Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators. Nature Communications, 2014, 5, 3897.	5.8	51
49	A highly sensitive method for in vitro testing of fluorinated drug candidates using high-resolution continuum source molecular absorption spectrometry (HR-CS MAS). Analytical and Bioanalytical Chemistry, 2014, 406, 3431-3442.	1.9	10
50	Synthesis, Characterization, and in vitro Antiproliferative Activity of [Salophene]platinum(II) Complexes. ChemMedChem, 2014, 9, 1176-1187.	1.6	14
51	Synthesis and In Vitro Pharmacological Behavior of Platinum(II) Complexes Containing 1,2-Diamino-1-(4-fluorophenyl)-2-alkanol Ligands. Journal of Medicinal Chemistry, 2013, 56, 7951-7964.	2.9	25
52	Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chemical Society Reviews, 2013, 42, 755-773.	18.7	672
53	Recent methodological and instrumental development in <scp>MEKC</scp> . Electrophoresis, 2013, 34, 1295-1303.	1.3	32
54	Nonsteroidal Bivalent Estrogen Ligands: An Application of the Bivalent Concept to the Estrogen Receptor. ACS Chemical Biology, 2013, 8, 707-715.	1.6	22

#	Article	IF	CITATIONS
55	Development and validation of a LC method for the separation and determination of the anticancer-active Fe ^{III} (4-methoxy-salophene) using the new second-generation monolith. Journal of Separation Science, 2012, 35, 3434-3438.	1.3	8
56	Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6076-6080.	1.0	6
57	Influence of Chlorine or Fluorine Substitution on the Estrogenic Properties of 1-Alkyl-2,3,5-tris(4-hydroxyphenyl)-1 <i>H</i> -pyrroles. Journal of Medicinal Chemistry, 2012, 55, 9607-9618.	2.9	17
58	Synthesis and in vitro antitumor activity of novel scopoletin derivatives. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5008-5012.	1.0	53
59	Characterization of Telmisartanâ€Derived PPARγ Agonists: Importance of Moiety Shift from Positionâ€6 toâ€ on Potency, Efficacy and Cofactor Recruitment. ChemMedChem, 2012, 7, 1935-1942.	⁵ 1.6	6
60	Synthesis, Characterization, and in Vitro Studies of Bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) Complexes. Journal of Medicinal Chemistry, 2012, 55, 3713-3724.	2.9	94
61	Synthesis, Antitumor, and Antibacterial Activity of Bis[4,5â€diarylimidazolâ€2â€ylidene]methane Derivatives. Archiv Der Pharmazie, 2012, 345, 557-564.	2.1	7
62	Synthesis, characterization and inÂvitro antitumour activity of a series of novel platinum(II) complexes bearing Schiff base ligands. European Journal of Medicinal Chemistry, 2012, 53, 168-175.	2.6	46
63	Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2701-2704.	1.0	44
64	Quantification of the fluorine containing drug 5-fluorouracil in cancer cells by GaF molecular absorption via high-resolution continuum source molecular absorption spectrometry. Spectrochimica Acta, Part B: Atomic Spectroscopy, 2012, 69, 50-55.	1.5	38
65	Determination of Nill(3-OMe-salophene) in MCF7 and HT29 cancer cell lines using HR-CS-AAS and in serum albumin using LC with monolithic silica. Microchemical Journal, 2012, 101, 24-29.	2.3	9
66	NHC Gold Halide Complexes Derived from 4,5-Diarylimidazoles: Synthesis, Structural Analysis, and Pharmacological Investigations as Potential Antitumor Agents. Journal of Medicinal Chemistry, 2011, 54, 8605-8615.	2.9	136
67	Synthesis and biological studies of silver N-heterocyclic carbene complexes derived from 4,5-diarylimidazole. European Journal of Medicinal Chemistry, 2011, 46, 5927-5934.	2.6	55
68	Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives. European Journal of Medicinal Chemistry, 2011, 46, 907-913.	2.6	34
69	MEKC as a powerful growing analytical technique. Electrophoresis, 2011, 32, 166-183.	1.3	87
70	Synthesis and Investigations on the Oxidative Degradation of C3/C5â€Alkylâ€1,2,4â€ŧriarylpyrroles as Ligands for the Estrogen Receptor. ChemMedChem, 2011, 6, 794-803.	1.6	22
71	Development of 2,3,5â€Triarylâ€1 <i>H</i> â€pyrroles as Estrogen Receptor α Selective Ligands. ChemMedCh 2011, 6, 2055-2062.	em. 1.6	4
72	Effects of Metal Salophene and Saldach Complexes on Lymphoma and Leukemia Cells. Archiv Der Pharmazie, 2011, 344, 217-223.	2.1	16

#	Article	IF	CITATIONS
73	Synthesis and Biological Activities of 2â€Aminoâ€thiazoleâ€5â€carboxylic Acid Phenylamide Derivatives. Archiv Der Pharmazie, 2011, 344, 451-458.	2.1	14
74	Synthesis, Characterisation and Biological Evaluation of Copper and Silver Complexes based on Acetylsalicylic Acid. Archiv Der Pharmazie, 2011, 344, 684-688.	2.1	17
75	Licofelone–Nitric Oxide Donors as Anticancer Agents. Archiv Der Pharmazie, 2011, 344, 487-493.	2.1	7
76	Conformational Analysis of Bivalent Estrogen Receptor Ligands: From Intramolecular to Intermolecular Binding. ChemBioChem, 2011, 12, 2587-2598.	1.3	28
77	Bivalent bendamustine and melphalan derivatives as anticancer agents. European Journal of Medicinal Chemistry, 2011, 46, 1604-1615.	2.6	21
78	[FeIII(salophene)Cl], a potent iron salophene complex overcomes multiple drug resistance in lymphoma and leukemia cells. Leukemia Research, 2011, 35, 387-393.	0.4	31
79	Synthesis and Biological Evaluation of Licofelone Derivatives as Anticancer and Anti-inflammatory Agents. Letters in Drug Design and Discovery, 2011, 8, 911-917.	0.4	4
80	Characterization of new PPARγ agonists: Benzimidazole derivatives—importance of positions 5 and 6, and computational studies on the binding mode. Bioorganic and Medicinal Chemistry, 2010, 18, 5885-5895.	1.4	26
81	2-Phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: Synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry, 2010, 18, 4905-4916.	1.4	15
82	[Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents. European Journal of Medicinal Chemistry, 2010, 45, 5157-5163.	2.6	27
83	Influence of methoxy groups on the antiproliferative effects of [FeIII(salophene-OMe)Cl] complexes. European Journal of Medicinal Chemistry, 2010, 45, 5486-5492.	2.6	27
84	Synthesis and Biological Activities of Transition Metal Complexes Based on Acetylsalicylic Acid as Neo-Anticancer Agents. Journal of Medicinal Chemistry, 2010, 53, 6889-6898.	2.9	50
85	Platinum(II)â^'Dendrimer Conjugates: Synthesis and Investigations on Cytotoxicity, Cellular Distribution, Platinum Release, DNA, and Protein Binding. Bioconjugate Chemistry, 2010, 21, 328-337.	1.8	55
86	[Ni ^{II} (3-OMe-salophene)]: A Potent Agent with Antitumor Activity. Journal of Medicinal Chemistry, 2010, 53, 6064-6070.	2.9	42
87	Optimization of the N-Lost Drugs Melphalan and Bendamustine: Synthesis and Cytotoxicity of a New Set of Dendrimerâ 'Drug Conjugates as Tumor Therapeutic Agents. Bioconjugate Chemistry, 2010, 21, 1728-1743.	1.8	20
88	Characterization of New PPARγ Agonists: Analysis of Telmisartan's Structural Components. ChemMedChem, 2009, 4, 445-456.	1.6	38
89	Characterization of New PPARγ Agonists: Benzimidazole Derivatives - the Importance of Positionâ€2. ChemMedChem, 2009, 4, 1136-1142.	1.6	22
90	Cytotoxic Rhodium(III) Polypyridyl Complexes Containing the Tris(pyrazolyl)methane Coligand: Synthesis, DNA Binding Properties and Structure-Activity Relationships. European Journal of Inorganic Chemistry, 2009, 2009, 3821-3831.	1.0	26

#	Article	IF	CITATIONS
91	Modulation of the Biological Properties of Aspirin by Formation of a Bioorganometallic Derivative. Angewandte Chemie - International Edition, 2009, 48, 1160-1163.	7.2	110
92	Breast Cancer, Estrogen Receptor and Ligands. Archiv Der Pharmazie, 2009, 342, 133-149.	2.1	100
93	Relationship Between Anticancer Activity and Stereochemistry of Saldach Ligands and their Iron(III) Complexes. Archiv Der Pharmazie, 2009, 342, 625-631.	2.1	19
94	[N,N′-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting properties. Journal of Biological Inorganic Chemistry, 2009, 14, 711-725.	1.1	80
95	Optimization of cisplatin for the treatment of hormone dependent tumoral diseases. Coordination Chemistry Reviews, 2009, 253, 2742-2759.	9.5	91
96	Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases. Coordination Chemistry Reviews, 2009, 253, 2760-2779.	9.5	43
97	Atomic absorption spectrometric determination of the iridium content in tumor cells exposed to an iridium metallodrug. Journal of Pharmaceutical and Biomedical Analysis, 2008, 47, 938-942.	1.4	14
98	Investigations on Surface Modified Dendrimers: Enzymatic Hydrolysis and Uptake into MCFâ€7 Breast Cancer Cells. ChemMedChem, 2008, 3, 635-641.	1.6	8
99	Metallo-nucleosides: synthesis and biological evaluation of hexacarbonyl dicobalt 5-alkynyl-2′-deoxyuridines. Organic and Biomolecular Chemistry, 2008, 6, 73-80.	1.5	44
100	Cobaltâ^'Alkyne Complexes with Imidazoline Ligands as Estrogenic Carriers: Synthesis and Pharmacological Investigations. Journal of Medicinal Chemistry, 2008, 51, 7318-7322.	2.9	18
101	Alkyne hexacarbonyl dicobalt complexes in medicinal chemistry and drug development. Expert Opinion on Therapeutic Patents, 2008, 18, 327-337.	2.4	31
102	Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 95-110.	0.9	70
103	Structureâ^'Activity Relationship Study To Understand the Estrogen Receptor-Dependent Gene Activation of Aryl- and Alkyl-Substituted 1H-Imidazoles. Journal of Medicinal Chemistry, 2007, 50, 1475-1484.	2.9	82
104	Non Platinum Metal Complexes as Anti-cancer Drugs. Archiv Der Pharmazie, 2007, 340, 117-126.	2.1	511
105	Development of a Method for the Quantification of the Molar Gold Concentration in Tumour Cells Exposed to Gold-Containing Drugs. ChemMedChem, 2007, 2, 702-707.	1.6	52
106	Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on estrogen receptor alpha level and transcriptional activity in MCF-7 cells. Biochemical Pharmacology, 2007, 74, 1029-1038.	2.0	10
107	Mono- and Polynuclear [Alkylamine]platinum(II) Complexes of [1,2-Bis(4-fluorophenyl)ethylenediamine]platinum(II):Â Synthesis and Investigations on Cytotoxicity, Cellular Distribution, and DNA and Protein Binding. Journal of Medicinal Chemistry, 2006, 49, 1182-1190.	2.9	46
108	Dinuclear Alkylamine Platinum(II) Complexes of [1,2-Bis(4-fluorophenyl)ethylenediamine]platinum(II): Influence of Endocytosis and Copper and Organic Cation Transport Systems on Cellular Uptake. ChemMedChem, 2006, 1, 560-564.	1.6	19

#	Article	IF	CITATIONS
109	Stability, protein binding and thiol interaction studies on [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt. BioMetals, 2005, 18, 171-177.	1.8	30
110	Investigations on the Effects of Basic Side Chains on the Hormonal Profile of (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines. Journal of Medicinal Chemistry, 2005, 48, 466-474.	2.9	17
111	Antitumor-Active Cobaltâ^'Alkyne Complexes Derived from Acetylsalicylic Acid:Â Studies on the Mode of Drug Action. Journal of Medicinal Chemistry, 2005, 48, 622-629.	2.9	202
112	Synthesis and Pharmacological Evaluation of 1H-Imidazoles as Ligands for the Estrogen Receptor and Cytotoxic Inhibitors of the Cyclooxygenase. Journal of Medicinal Chemistry, 2005, 48, 6516-6521.	2.9	66
113	[N-Ethyl- and [N,Nâ€~-Diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II): Structure and Cytotoxic/Estrogenic Activity in Breast Cancer Cells. Journal of Medicinal Chemistry, 2005, 48, 7132-7144.	2.9	12
114	Synthesis, cytotoxicity, cellular uptake and influence on eicosanoid metabolism of cobalt–alkyne modified fructoses in comparison to auranofin and the cytotoxic COX inhibitor Co-ASS. Organic and Biomolecular Chemistry, 2005, 3, 2282.	1.5	46
115	A Surface-Modified Dendrimer Set for Potential Application as Drug Delivery Vehicles: Synthesis, In Vitro Toxicity, and Intracellular Localization. Chemistry - A European Journal, 2004, 10, 1167-1192.	1.7	107
116	A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorganic and Medicinal Chemistry, 2004, 12, 6527-6537.	1.4	31
117	Investigations on the effects of cobalt-alkyne complexes on leukemia and lymphoma cells: cytotoxicity and cellular uptake. Journal of Inorganic Biochemistry, 2004, 98, 485-489.	1.5	64
118	Development of Cobalt(3,4-diarylsalen) Complexes as Tumor Therapeutics. Journal of Medicinal Chemistry, 2004, 47, 5837-5846.	2.9	100
119	Effects of C2-Alkylation, N-Alkylation, and N,Nâ€~-Dialkylation on the Stability and Estrogen Receptor Interaction of (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines. Journal of Medicinal Chemistry, 2004, 47, 915-927.	2.9	27
120	Invesgations on the Influence of Halide Substituents on the Estrogen Receptor Interaction of 2, 4, 5-Tris(4-hydroxyphenyl)imidazoles. Archiv Der Pharmazie, 2003, 336, 456-465.	2.1	18
121	Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 57-70.	1.2	5
122	Structure activity relationship studies on C2 side chain substituted 1,1-bis(4-methoxyphenyl)-2-phenylalkenes and 1,1,2-tris(4-methoxyphenyl)alkenes. Journal of Steroid Biochemistry and Molecular Biology, 2003, 87, 75-83.	1.2	2
123	(4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines:Â Ligands for the Estrogen Receptor with a Novel Binding Mode. Journal of Medicinal Chemistry, 2002, 45, 3356-3365.	2.9	33
124	Synthesis, Structural Evaluation, and Estrogen Receptor Interaction of 2,3-Diarylpiperazines. Journal of Medicinal Chemistry, 2002, 45, 2325-2337.	2.9	29
125	Investigations on Estrogen Receptor Binding. The Estrogenic, Antiestrogenic, and Cytotoxic Properties of C2-Alkyl-Substituted 1,1-Bis(4-hydroxyphenyl)-2-phenylethenes. Journal of Medicinal Chemistry, 2002, 45, 5358-5364.	2.9	43
126	Synthesis, Structural Evaluation, and Estrogen Receptor Interaction of 4, 5-Bis(4-hydroxyphenyl)imidazoles. Archiv Der Pharmazie, 2002, 335, 463-471.	2.1	17

#	Article	IF	CITATIONS
127	Investigations of New Lead Structures for the Design of Selective Estrogen Receptor Modulators. Journal of Medicinal Chemistry, 2001, 44, 1963-1970.	2.9	35
128	Acetylenehexacarbonyldicobalt complexes, a novel class of antitumor drugs. Inorganica Chimica Acta, 2000, 306, 6-16.	1.2	90
129	Gold complexes with thiosemicarbazones: reactions of bi- and tridentate thiosemicarbazones with dichloro[2-(dimethylaminomethyl)phenyl-C 1,N ]gold(III), [Au(damp-C 1,N )Cl2]. Dalton Transactions 2000, , 735-744.	RS£,	92
130	Structure Activity Studies on Leaving Group Derivatives of [meso-1,2-Bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]-platinum(II). Archiv Der Pharmazie, 1999, 332, 261-270.	2.1	7
131	Stability and cellular studies of [rac -1,2-bis(4-fluorophenyl)- ethylenediamine][cyclobutane-1,1-dicarboxylato]platinum(II), a novel, highly active carboplatin derivative. Journal of Cancer Research and Clinical Oncology, 1998, 124, 585-597.	1.2	46
132	Third Generation Antitumor Platinum(II) Complexes of the [1-(Fluoro/difluorophenyl)-2-phenylethylenediamine]platinum(II) Type. Archiv Der Pharmazie, 1995, 328, 595-603.	2.1	5
133	Investigation of the Configurational and Conformational Influences on the Hormonal Activity of 1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their Platinum(II) Complexes. 1. Synthesis, Estradiol Receptor Affinity, and Estrogenic Activity of Diastereomeric [N-Alkyl- and N,N'-Dialkyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) Complexes.	2.9	23
134	Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]-sulfatoplatinum(II), a New Compound for the Treatment of the Mammary Carcinoma. Archiv Der Pharmazie, 1994, 327, 49-54.	2.1	6
135	Crystal structure, solution chemistry, and antitumor activity of diastereomeric [1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes. Inorganic Chemistry, 1993, 32, 5939-5950.	1.9	31
136	Tumor Inhibiting [1,2-Bis(fluorophenyl)ethylenediamine]platinum(II) Complexes. Part IV: Biological Evaluation -in vivo Studies on the P 388 Leukemia. Archiv Der Pharmazie, 1991, 324, 405-409.	2.1	8
137	Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine](sulfato)platinum(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties. Journal of Medicinal Chemistry, 1990, 33, 2535-2544.	2.9	72
138	Tumor Inhibiting Properties of Stereoisomeric [1,2-Bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-Complexes, Part I: Synthesis. Archiv Der Pharmazie, 1989, 322, 25-29.	2.1	13
139	Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma. Journal of Medicinal Chemistry, 1988, 31, 72-83.	2.9	101